Upload
preston-mitchell
View
49
Download
1
Tags:
Embed Size (px)
DESCRIPTION
ICIUM 2011 Conference Antalya, Turkey. 4 th - 18 November 2011. Experiences and use of the MeTA Data Disclosure Survey Tools in GHANA. Daniel Kojo Arhinful No guchi Memorial Institute for Medical Research University of Ghana. Introduction. - PowerPoint PPT Presentation
Citation preview
4th - 18 November 2011
ICIUM 2011 Conference Antalya, Turkey
19/04/23
Daniel Kojo ArhinfulNo guchi Memorial Institute for Medical Research
University of Ghana
Experiences and use of the MeTA Data Disclosure Survey Tools in GHANA
07/12/2009 2
Introduction
MeTA’s overall goal is to increase access to essential medicines for the poorest of the poor in developing countries
Ghana and other MeTA pilot countries are developing strategies to promote greater transparency & accountability regarding policies, practices, and outcomes through data disclosure
MeTA 19/04/23 3
Why Disclosure?
Objectives– Enable national MeTA stakeholders to prioritize
country activities to facilitate progressive disclosure over time;
– Create a baseline against which changes in transparency and disclosure during the MeTA pilot implementation can be measured
Consonance with MeTA’s overall goal to increase access to essential medicines for the poorest in developing countries
MeTA 19/04/23 4
Core areas of Data Disclosure
Medicines registration and quality assurance Availability of medicines Price of medicines Policies and practices concerning the promotion
of medicines
MeTA 19/04/23 5
Scope of Information Disclosure
Policies – the laws and regulations that are in place;
Practices – suggested procedures to follow and actual practices; and
Results –achievements in the core area
MeTA 19/04/23 6
Scope of Questions
Policies: Do laws/policies exist? Are they published? Do associated regulations exist?
Practices: Are procedures published? How enforced? Which data exist? Who has access?
Results: Which data are available? Who uses data? Barriers to use? How to promote wider use?
MeTA 19/04/23 7
Process of Data Collection Tool developed by Harvard Group Identification of Key Respondents Questionnaire administered to key Informants Initial discussion of results by technical sub-
group Re-Visits where necessary to validate results Discussion of results by Governing Council Dissemination and discussion by multi-
stakeholder Group
MeTA 19/04/23 8
EXPERIENCE AND USE OF THE TOOL
How did the tools fare?
19/04/23MeTA
9
Policies of Data Disclosure Do Policies exist? Are they published? Do
associated regulations exist? Very useful in unearthing various policies practices and existing
results. Examples of existing policies: Drug regulation - Food and Drugs Law, P.N.D.C.L 305B, 1992
Customs Excise and Preventive Service (Management) Law 1993; Value Added Tax Act 1998 (Act 546); Public Procurement Act 663 (2003); National Health Insurance Act 2003 (Act 650) and Regulation 2004, (L.I.1809); National Drug Policy (MOH), 2004
MeTA 19/04/23 10
Are practices published? YES
– Available for sale at Assemblies Press, GPC– Distributed free of charge e.g. Drug Policy– Websites e.g.: http://www.fdbghana.gov.gh/
http://ghanastandards.org/
– Standard Operating Procedures (SOPs) e.g. – Internal Document not usually in public domain – Egs.
Central Medical Stores Analytical Reports Tender Procurement Evaluation reports Quantities and cost of available medicines
MeTA 19/04/23 11
Who has access to existing data?
Everyone? – Law makes it mandatory for anybody to have
access but more often…… Various entities (technical assistance providers and
programme implementers, health care providers, regulators, importers, manufacturers, researchers, students, donors & multilateral agencies)
MeTA 19/04/23 12
What are the barriers to disclosure
Culture of non-disclosure despite existing laws & policy
Dealing with sensitivities of various interest groups
Mistrust among stakeholders Low literacy among the population Dormant consumer groups Key websites are not updated regularly Lack of resources to disseminate widely Right to Information Bill yet to be passed into
legislation 19/04/23
Recommendations on how to promote wider disclosure
Broader engagement of key stakeholders in a very transparent manner
Promote public awareness & education on medicines access
More copies of reports printed to meet increasing demand.
Create more awareness in the media & community groups/CSO
Maintenance of key websites eg. MoH, FDB, GSS & NDIRC
19/04/23
Summary and Conclusions Data disclosure among multi-stakeholder group
provided the following benefits: Stimulated discussion Provided grounds to share and learn among various
stakeholders Provided understanding of existing problems Highlighted challenges for working among multi
stakeholder groups Raised useful questions and led to important
recommendations
19/04/23